Our laboratory is at the forefront of hematopoietic stem cell (HSC) transplantation research, striving to unlock the molecular intricacies that dictate HSC cell fate. Our ultimate goal is to pioneer molecular programs and bioengineering technologies that will pave the way for innovative HSC products for cellular therapy.
We delve into the epi-transcriptomic regulation of hematopoietic stem and progenitor cells, exploring reversible epigenetic marks and their impact on mRNA stability. Through CRISPR-Cas9 gene-editing, we aim to develop transformative treatments for Sickle Cell Disease. Our holistic approach encompasses robust systems biology and integrative methodologies to construct gene-regulatory networks, which are rigorously tested to identify key drivers of HSC fate.
Our team is composed of scientists (biologists, engineers, and medical professionals) from diverse backgrounds united by a shared quest for knowledge and a commitment to advancing the realm of cellular therapy.
At the Maganti Lab, we champion a culture of inclusivity, acknowledging that diverse perspectives drive scientific excellence. We are committed to fostering an environment where every member feels valued, respected, and empowered to contribute their unique insights and skills. Our collaborative ethos is enriched by a variety of experiences and backgrounds. By embracing diversity in all its forms, we aim to create a vibrant community propelling our collective endeavour towards groundbreaking discoveries in the field of hematopoietic stem cell research and its therapeutic applications.